Perinatal Infections Fetal Infection

Содержание

Слайд 2

Infections Toxoplasmosis Rubella Varicella Parvovirus CMV HIV Syphilis

Infections

Toxoplasmosis
Rubella
Varicella
Parvovirus
CMV
HIV
Syphilis

Слайд 3

Introduction 3% of the perinatal mortalities are related to (fetal infection)

Introduction

3% of the perinatal mortalities are related to (fetal infection)
Fetus can

be affected at any gestational age
Most severe affection occurs in the first trimester
Most of the fetal infections are preventable
Слайд 4

Red indicates the most vulnerable period of development. (Moore 143).

Red indicates the most vulnerable period of development. (Moore 143).

Слайд 5

First Trimester Organogenesis Growth restriction Second and Third Trimester Neuological Impairment Growth restriction

First Trimester
Organogenesis
Growth restriction
Second and Third Trimester
Neuological Impairment
Growth restriction

Слайд 6

Think of fetal infection I.U.G.R Hepatic Calcification Intracrainal Calcification Hydrocephally, Microcephally

Think of fetal infection

I.U.G.R
Hepatic Calcification
Intracrainal Calcification
Hydrocephally, Microcephally
Ascits
Pericardial,Pleural Effusion
Non Immune Hydrops

Fetalis
Слайд 7

Слайд 8

Слайд 9

Слайд 10

Слайд 11

Слайд 12

Слайд 13

Toxoplasmosis - Toxoplasmon gondii (intracellular parasite) Trans-placental affect the placenta fetus

Toxoplasmosis

- Toxoplasmon gondii (intracellular parasite)
Trans-placental affect the placenta fetus
Transmission Rate
- 10

–15% 1st trimester
- 25% 2nd trimester
- 60% 3rd trimester
Слайд 14

Слайд 15

Toxoplasmosis Toxoplasmosis - Incidence of congenital toxoplasmosis - 0.07 – 0.5

Toxoplasmosis

Toxoplasmosis
- Incidence of congenital toxoplasmosis
- 0.07 – 0.5 : 1000 London
-

2 : 1000 Brussels
- 3.22 : 1000 Paris
Слайд 16

Risks to the Fetus 1st Trimester - 55 – 85% will

Risks to the Fetus

1st Trimester
- 55 – 85% will show

sequilie
- Chrioretinitis severe impairment of vision
- Hearing loss
- Mental Retardation
- Ascits
- Periventirecular Calcification
- Hydrocephally
Слайд 17

Toxoplasmonsis Ultra Sound - Intracranial, hepatic, calcification - Ascitis - Hepatosplenomegally

Toxoplasmonsis
Ultra Sound
- Intracranial, hepatic, calcification
- Ascitis
- Hepatosplenomegally
- Microcephally
- I.U.G.R
Diagnosis Fetal Blood

Sampling
- IgM
- PCR
- Culture
Слайд 18

Toxoplasmosis Treatment - Reduce risk of transmission Spiramycin - If fetal

Toxoplasmosis

Treatment
- Reduce risk of transmission
Spiramycin
- If fetal infection documented
- Pyrimethamine
-

Sulfadiazine….. Folic acid
Слайд 19

Pyron F, Wallonlion C, Goner P, Cochrane Database Review January 2005

Pyron F, Wallonlion C, Goner P,
Cochrane Database Review
January 2005
Objective
To assess whether

treatment of toxoplasmosis reduces the risk of congenital toxoplasmosis
Selection Criteria
RCT
- Antibiotics
- No treatment
Proven Infection
Слайд 20

Look, outcome of the children 3332 Papers identified

Look, outcome of the children
3332 Papers identified

Слайд 21

NO Trial fulfill the criteria

NO Trial fulfill the criteria

Слайд 22

Conclusion We do not know whether antibiotics Treatment reduces the congenital

Conclusion
We do not know whether antibiotics Treatment reduces the congenital transmission

or not.
Screening is Expensive
Screening is not recommended in countries where screening and treatment is not routine.
Слайд 23

Toxoplasmosis Prevention to Toxoplasmosis: Advice to Pregnant Women whose Serological Tests

Toxoplasmosis

Prevention to Toxoplasmosis: Advice to Pregnant Women whose Serological Tests

are Negative.
Cook meat at 60oC + (Industrial deep-freezing also seems to destroy parasites efficiently).
When handling raw meat, do not touch eyes or mouth.
Слайд 24

Cont.. Prevention of Toxoplasmosis Carefully wash hands after handling raw meat,

Cont.. Prevention of Toxoplasmosis

Carefully wash hands after handling raw meat,

dirt, or vegetables soiled by dirt.
Wash fruit and vegetables before eating
Wear gloves when gardening
Avoid all contacts with things that may have
been contaminated by cat feces
If the cat’s litter has to be changed, put on
gloves and disinfect often with boiling water.
Слайд 25

Слайд 26

Слайд 27

Слайд 28

Слайд 29

Слайд 30

Слайд 31

Слайд 32

Rubella German Measles Rubella - 3rd Disease RNA Virus - Respiratory

Rubella German Measles

Rubella
- 3rd Disease
RNA Virus
- Respiratory secretions
- 2 – 3

weeks I.P.
Слайд 33

Rubella - 0.5 – 2% Non Immune - 0.2 – 0.5

Rubella

- 0.5 – 2% Non Immune
- 0.2 – 0.5 Congenital Rubella

Syndrome
Risk of Transmission
- 8 – 12 weeks 90%
-12 – 16 weeks 50%
- 16 – 20 weeks 17%
Слайд 34

Rubella Ultra Sound - I.U.G.R. - Hepto-splenomegally Congenital Rubella syndrome -

Rubella

Ultra Sound - I.U.G.R.
- Hepto-splenomegally
Congenital Rubella syndrome
- Eye


Cataract, Retinopathy
Microphthalmia, glaucoma
- Ear
Deafness
-Heart PDA
Слайд 35

Rubella Diagnosis IgM

Rubella
Diagnosis
IgM

Слайд 36

RUBELLA Prevention Active immunization by vaccination is the only efficient way of preventing congenital rubella.

RUBELLA
Prevention
Active immunization by vaccination is the only efficient way

of preventing congenital rubella.
Слайд 37

Слайд 38

Слайд 39

Varicella Zoster Virus DNA Herpes - Chickenpox - Herpes Zoster -

Varicella Zoster Virus DNA Herpes
- Chickenpox
- Herpes Zoster
- Incidence in pregnancy

0.4 – 0.7 : 1000
Maternal
- Pneumonia increase mortality
Fetal Congenital Varicella Syndrome in 1st tri mester
- Skin Scar, Limb Hyproplasia
- Chrioretinitis, Microcephally
Слайд 40

Varicella Neonatal Infection Increase in Mortality - 5 days before delivery

Varicella

Neonatal Infection
Increase in Mortality
- 5 days before delivery – 48 hours

post partum
- Avoid delivery if possible in this period
Слайд 41

Diagnosis Viral Culture - PCR Presence of infection does not predicate the severity of the disease

Diagnosis

Viral Culture
- PCR
Presence of infection does not predicate the severity of

the disease
Слайд 42

VARICELLA Prevention Passive immunization is currently available and should be administered

VARICELLA
Prevention
Passive immunization is currently available
and should be

administered within 24-72
hours to sero-negative pregnant patients who
have been exposed to varicella.
Слайд 43

Varicella Treatment - Oral cyclovir to improve sysmatic I.V. to treat

Varicella

Treatment
- Oral cyclovir to improve sysmatic I.V. to treat pneumonia
- Safe

in Pregnancy
- Does not prevent or decrease the fetal effect
- VZIG to be given to the neonate 5 days before delivery – 2 days postpartum
Слайд 44

Varicella Screening - Not Recommended

Varicella
Screening
- Not Recommended

Слайд 45

Слайд 46

Слайд 47

Parvovirus B.19 the fifth disease Infectious period 5 – 10 days

Parvovirus B.19 the fifth disease
Infectious period 5 – 10 days after

exposure
Mode of transmission
- Transplacental 33% transmission risk
- Fetal effect – abortion <20 weeks
- Hydrops fetalis 18% of all non immune
Слайд 48

Intrauterine fetal infection Fetal effect of B19 : - A symptomatic

Intrauterine fetal infection

Fetal effect of B19 : - A symptomatic - IUGR -

Congenital anomalies - Hydrops fetalis - IUFD
Parvovirus B 19 pathogenesis: a) Anemia b) Fetal myocardium and hepatic affection c) Vasculitis
Слайд 49

Diagnosis Parpovirus - ELISA -Western blot test IGM Diagnosis of Primary

Diagnosis

Parpovirus
- ELISA
-Western blot test
IGM Diagnosis of Primary Infection
Elect Microscopy
- Direct Visualization

of the virus or viral particles
Слайд 50

Parvovirus Fetal Diagnosis PCR in A.F., Placenta & Blood Ultra Sound Hydropy Fetalis

Parvovirus

Fetal Diagnosis
PCR in A.F., Placenta & Blood
Ultra Sound
Hydropy Fetalis

Слайд 51

Parvovirus Prognosis and therapy Survivor recovers normal Fetal Therapy Intravascualr Intrauterine Blood Transfusion

Parvovirus

Prognosis and therapy
Survivor recovers normal
Fetal Therapy
Intravascualr Intrauterine Blood Transfusion

Слайд 52

Слайд 53

Слайд 54

Слайд 55

CMV DNA Herpes Virus Most common perinatal infection 0.2 – 2%

CMV
DNA Herpes Virus
Most common perinatal infection
0.2 – 2% of all

newborns
Leading cause of hearing loss
Mode of transmission
Contact with infected
-Blood
-Urine
-Salvia
-Sexual contact
Слайд 56

CMV I.P 28 – 60 days Viremia 2 – 3 weeks

CMV

I.P 28 – 60 days
Viremia 2 – 3 weeks
Maternal effect –


Asympathic, mild fever, malaise & myalgia
Primary infection 0.7 – 4%
Recurrent infection 13.5%
Слайд 57

Epidimulogical Facts Primary Infection -Risk of Transmission 30 – 40% -10%

Epidimulogical Facts
Primary Infection
-Risk of Transmission 30 – 40%
-10% Seguilie of the

infected
-30% Prenatal Mortality
-Of the survivor 80%will have neurological damage
Слайд 58

Recurrent Infection Transmission 0.1 – 2% Mostly a symptomatic most of

Recurrent Infection
Transmission 0.1 – 2% Mostly a symptomatic most of the

sequilie occurs as hearing loss
Слайд 59

Diagnosis CMV Diagnosis Culture or PCR – blood, urine & salvia

Diagnosis

CMV
Diagnosis Culture or PCR
– blood, urine & salvia
IgG Serial Measurements

3 – 4 weeks
Diagnosis either by seroconversion
Or increase titer by more than 4 folds
-1 : 4 – 1: 16
-1 : 16 – 1 : 256
Слайд 60

IGM is not reliable as it may be negative even in

IGM is not reliable as it may be negative even in

the right phase and may persist for months after infections
Слайд 61

Diagnosis Fetal Diagnosis Ultra Sound System - Intracrainal or hepatic calcification

Diagnosis

Fetal Diagnosis Ultra Sound System
- Intracrainal or hepatic calcification
- Echogenic bowel
-

Ascits
A.F.
- Culture
- PCR
Слайд 62

CMV Treatment - Not available - Neonatal therapy ganciclovir may decrease

CMV
Treatment
- Not available
- Neonatal therapy ganciclovir may decrease neonatal infections
Vaccine
- May

Reactivate A previous infection
CMV
Screening
Not Recommended
Слайд 63

Слайд 64

Слайд 65

Слайд 66

Слайд 67

Human immunodeficiency virus (HIV) Infection This is the major cause of

Human immunodeficiency virus (HIV) Infection

This is the major cause of

congenital
infection in the developing world.
Over one million children had been
infected from their mother by the end of 1998.
Слайд 68

Mother ? child in utero at birth breast milk Organ/tissue donation

Mother ? child
in utero
at birth
breast milk
Organ/tissue donation
Semen
Kidneys
Skin, bone

marrow, corneas, heart valves, tendons, etc.
Слайд 69

TO SCREEN OR NOT TO SCREEN? The best defense is a

TO SCREEN OR NOT TO SCREEN?

The best defense is a strong

offense.
The American Academy of Paediatrics and the ACOG issued a Joint Statement on HIV Screening in Pregnancy (1999) (2001).
A pregnant women should receive HIV counseling as part of their routine ANC.
A pregnant women should have HIV testing with their consent.
Слайд 70

PRE-TEST COUNSELING Risks of transmission (including Mode) Risks of perinatal transmission

PRE-TEST COUNSELING

Risks of transmission (including Mode)
Risks of perinatal transmission
Potential social and

psychological implication of Positive test.
The availability of Agents that may reduce the risk of neonatal infection.
Clarify the difference between HIV infection and disease.
Слайд 71

Timing of Perinatal HIV Transmission Cases documented intrauterine, intrapartum, and postpartum

Timing of Perinatal HIV Transmission

Cases documented intrauterine, intrapartum, and postpartum

by breastfeeding
In utero - 25% 40% of cases
Intrapartum- 60% 75% of cases
Addition risk with breastfeeding
14% ?risk with established infection
29% ?risk with primary infection
Current evidence suggests most transmission occurs during the intrapartum period
Слайд 72

Factors Influencing Perinatal Transmission Maternal Factors HIV-1 RNA levels (viral load)

Factors Influencing Perinatal Transmission

Maternal Factors
HIV-1 RNA levels (viral load)
Low CD4

lymphocyte count
Other infections, Hepatitis C, CMV, bacterial vaginosis
Maternal infection drug use
Lack of ZDV during pregnancy
Obstetrical Factors
Length of ruptured membranes/chorioamnionitis
Vaginal delivery
Invasive procedures
Infant Factors
Prematurity
Слайд 73

Reducing HIV Transmission with Suboptimal Regimens Partial ZDV regimens: ( New

Reducing HIV Transmission with Suboptimal Regimens

Partial ZDV regimens: ( New

York cohort)
Transmission rates
6.1% with prenatal, intrapartum, and infant ZDV
10% with only intrapartum ZDV
9.3% if only infant ZDV started within first 48 hours
26.6% with no ZDV
Слайд 74

Reducing Intrapartum HIV Transmission: Studies of Short Course Therapy Oral ZDV

Reducing Intrapartum HIV Transmission: Studies of Short Course Therapy

Oral

ZDV in a non-breastfeeding population (Thailand) from 36 weeks and during labor
Transmission rate: 9.4% ZDV vs. 18.9% placebo
PETRA study – intrapartum/postpartum oral ZDV/3TC in a breast-feeding population (Uganda, S. Africa, Tanzania)
Transmission rate: 10% ZDV/3TC vs. 17% placebo
HIV Net 012 – intrapartum/postpartum/neonatal Nevirapine (NVP) vs. short course/neonatal ZDV in a breast-feeding population (Uganda)
Transmission rate: 12% NVP vs. 21% ZDV
Слайд 75

Treatment with zidovudine appears to be safe in pregnancy. Elective caesarean section may decrease mother-to-child transmission.

Treatment with zidovudine appears to be safe in pregnancy.
Elective

caesarean section may decrease mother-to-child transmission.
Слайд 76

HIV Chochrane Database 2002 Objective to assess what intervention will decrease

HIV
Chochrane Database 2002
Objective to assess what intervention will decrease the risk

of mother to children transmission of HIV
Слайд 77

AZT 4 trials decrease 1585 patients Neviropine compared AZT 626 decrease

AZT
4 trials decrease 1585 patients
Neviropine compared AZT 626 decrease transmission
C/S one

trial 436 patients decrease risk of transmission
Immunoglbullin
Does not decrease the risk
Слайд 78

Conclusion Zidoridine, Nevirpine C/S decreases the transmission significantly.

Conclusion
Zidoridine, Nevirpine
C/S decreases the transmission significantly.

Слайд 79

Syphilis - T.P. - Increase HIV Transmission all through

Syphilis
- T.P.
- Increase HIV
Transmission all through

Слайд 80

Manifestation Ultra Sound Thick Placenta Hydrops fetalis I.U.G.R Hydroamnios – Hepato-splenomegaly

Manifestation
Ultra Sound
Thick Placenta
Hydrops fetalis
I.U.G.R
Hydroamnios – Hepato-splenomegaly ……
Risk of Transmission
90%

primary
50% secondary
6 – 14% Latent Syphillis
Слайд 81

Diagnosis Screening Non Specific VDAL RPR Specific TPHA F.T.A. becomes ….. 3 – 4 weeks

Diagnosis
Screening Non Specific
VDAL
RPR
Specific
TPHA
F.T.A. becomes …..
3 – 4

weeks
Слайд 82

Treatment - Penicillin - Benzathin Penicillin 2.4 million unit - Erythpromycine

Treatment
- Penicillin
- Benzathin Penicillin 2.4 million unit
- Erythpromycine

Слайд 83

Слайд 84

Слайд 85

Слайд 86

Слайд 87

Слайд 88